| 1 |
NCT03647124 |
Not yet recruiting |
Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- To quantify and characterize the event of TFR by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.
- To quantify and characterize the proportion of early deaths by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting
|
560 |
All |
18 Years and older (Adult, Older Adult) |
NCT03647124 |
CC-5013-MCL-005
U1111-1213-1816
EUPAS23366 |
PASS MCL-005 |
September 30, 2018 |
December 31, 2026 |
December 31, 2026 |
August 27, 2018 |
August 27, 2018 |
|
|
|
| 2 |
NCT02371577 |
Withdrawn |
Evaluation of the Immune Restoration Potential Of Lenalidomide |
- Chronic Lymphocytic Leukemia (CLL)
|
|
Interventional
|
Phase 2 |
- University of California, San Diego
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Immunoglobulin G level
- Treatment-emergent adverse events, including infections
- Progression free survival rate at 6 months, determined by International Working Group in CLL (iwCLL) criteria.
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02371577 |
141671 |
Revlimid |
February 1, 2017 |
December 2018 |
December 2020 |
February 25, 2015 |
April 28, 2017 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States
|
|
| 3 |
NCT03701711 |
Recruiting |
Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study |
- Demyelinating Sensorimotor Neuropathy
|
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03701711 |
2018H0150 |
|
September 10, 2018 |
June 30, 2020 |
September 30, 2020 |
October 10, 2018 |
October 16, 2018 |
|
- The Ohio State University Medical Center
Columbus, Ohio, United States
|
|
| 4 |
NCT02370888 |
Recruiting |
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease |
- Leukemia, Myeloid
- Myelodysplastic Syndromes
|
|
Interventional
|
Phase 1 |
- University of Florida
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of lenalidomide
- CD34+ mixed chimerism
|
24 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02370888 |
WIRB20151509
RV-CL-AML-PI-002987 |
UF-BMT-MRD-101 |
May 16, 2016 |
November 2018 |
May 2019 |
February 25, 2015 |
June 1, 2018 |
|
- University of Florida Shands Cancer Center
Gainesville, Florida, United States
|
|
| 5 |
NCT02302469 |
Completed |
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia |
- Waldenstrom Macroglobulinemia
|
|
Interventional
|
Phase 1
Phase 2 |
- University Hospital, Lille
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with dose limiting toxicities (DLT) of lenalidomide as a Measure of Safety and Tolerability.
- number of patients with a response to lenalidomide
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- (and 3 more...)
|
17 |
All |
18 Years and older (Adult, Older Adult) |
NCT02302469 |
2008_15/0837
2008-006370-15 |
RV-WM-0426 |
March 2009 |
March 2017 |
April 2017 |
November 27, 2014 |
June 7, 2017 |
|
- Centre Hospitalier de la côte basque
Bayonne, France - Ch Clermond Ferrand
Clermond Ferrand, France - CH LENS
Lens, France - (and 4 more...)
|
|
| 6 |
NCT02279654 |
Recruiting |
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Ascertain the Disease Progression to AML (through calculation of product limit estimators and incidence rates) for those with transfusion dependent Low to Intermediate 1 risk MDS del 5 q and have been treated with Revlimid
- Overall Survival for patients with transfusion-dependent low to intermediate 1 risk MDS and isolated del (5q) and who have been treated with Lenalidomide
- Adverse Events
- (and 2 more...)
|
1800 |
All |
18 Years and older (Adult, Older Adult) |
NCT02279654 |
CC-5013-MDS-010 |
PASS MDS del5q |
December 17, 2014 |
December 31, 2021 |
December 31, 2022 |
October 31, 2014 |
September 25, 2018 |
|
- AZ Klina
Brasschaat, Belgium - AZ Sint Jan
Brugge, Belgium - Hospital Erasm - 808 Route de lennik
Brussels, Belgium - (and 181 more...)
|
|
| 7 |
NCT02538965 |
Active, not recruiting
Has Results |
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International Working Group (IWG) Criteria
- Number of Participants Who Achieved a Bone Marrow Confirmed CR/CRi Lasting 3 Months (Durable Response Rate)
- Duration of Response
- (and 13 more...)
|
17 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02538965 |
CC-5013-AML-002 |
|
November 19, 2015 |
July 22, 2017 |
July 13, 2022 |
September 2, 2015 |
September 20, 2018 |
September 20, 2018 |
- Children's Hospital
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 59 more...)
|
|
| 8 |
NCT01750762 |
Terminated |
Lenalidomide After Allo Transplant |
|
|
Interventional
|
Phase 1 |
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability of lenalidomide
- Effect of lenalidomide on T-cells
- Effect of lenalidomide on disease response
- The effects of lenalidomide on time to progression
|
1 |
All |
18 Years and older (Adult, Older Adult) |
NCT01750762 |
12-086 |
|
December 2012 |
March 2014 |
March 2014 |
December 17, 2012 |
April 18, 2017 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
| 9 |
NCT02018523 |
Terminated |
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer |
- Carcinoma, Non-Small-Cell Lung
|
|
Interventional
|
Phase 1 |
- Jun Zhang
- Celgene Corporation
- Baylor College of Medicine
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Number of participants with adverse events
- Change in circulating immune cells
|
7 |
All |
18 Years and older (Adult, Older Adult) |
NCT02018523 |
H-32774 |
|
June 2014 |
August 2016 |
August 2016 |
December 23, 2013 |
January 18, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
|
| 10 |
NCT03302728 |
Not yet recruiting |
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma |
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Hodgkin Lymphoma
|
- Drug: Lenalidomide 15mg
- Drug: Brentuximab Vedotin 1.8 mg/Kg
|
Interventional
|
Phase 1 |
- Peter MacCallum Cancer Centre, Australia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of the combination of lenalidomide and brentuximab vedotin
- Safety profile of the combination of lenalidomide and brentuximab vedotin
- Treatment intensity.
- (and 4 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03302728 |
17/34 |
EpiBrentlen |
December 15, 2017 |
May 15, 2021 |
August 15, 2021 |
October 5, 2017 |
October 10, 2017 |
|
- Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
|
|
| 11 |
NCT02963610 |
Terminated |
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer |
- Relapsed or Refractory Solid Tumors
- Nonsmall Cell Lung Cancer
|
- Drug: Lenalidomide
- Drug: Pembrolizumab
|
Interventional
|
Phase 1
Phase 2 |
- Fox Chase Cancer Center
- Merck Sharp & Dohme Corp.
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the maximum tolerated dose (MTD) of lenalidomide in combination with a fixed dose of pembrolizumab in subjects with relapsed and/or refractory solid tumors.
- To determine efficacy as measured by progression free survival (PFS) in Non-small cell lung cancer patients
- Assess antitumor activity of the combination as measured by objective response rate (ORR)
- (and 8 more...)
|
3 |
All |
18 Years and older (Adult, Older Adult) |
NCT02963610 |
TH-088 |
|
March 29, 2017 |
October 3, 2017 |
March 20, 2018 |
November 15, 2016 |
June 14, 2018 |
|
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 12 |
NCT02126553 |
Recruiting |
Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission |
|
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse-Free Survival (RFS) With Lenalidomide Maintenance Therapy
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02126553 |
2014-0116
NCI-2014-01176 |
|
November 2014 |
November 2022 |
November 2023 |
April 30, 2014 |
February 12, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 13 |
NCT01724177 |
Completed
Has Results |
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma |
- Adult T-Cell Leukemia-Lymphoma
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)
- Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC
- Kaplan-Meier Estimate of Time to Progression (TTP)
- (and 4 more...)
|
26 |
All |
20 Years and older (Adult, Older Adult) |
NCT01724177 |
CC-5013-ATLL-002 |
|
November 12, 2012 |
November 20, 2014 |
March 21, 2017 |
November 9, 2012 |
May 28, 2018 |
January 5, 2016 |
- Nagoya City University Hospital
Nagoya, Aichi, Japan - National Cancer Center Hospital East
Kashiwa, Chiba, Japan - Ehime University Hospital
Toon, Ehime, Japan - (and 15 more...)
|
|
| 14 |
NCT03208218 |
Completed |
Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers |
|
- Drug: SYP-1512
- Drug: Revlimid cap
|
Interventional
|
Phase 1 |
- Samyang Biopharmaceuticals Corporation
- Chungnam National University Hospital
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics of the AUCt between SYP-1512 and Revlimid cap(25mg)
- Pharmacokinetics of the Cmax between SYP-1512 and Revlimid cap(25mg)
- Pharmacokinetics of the AUCinf SYP-1512 and Revlimid cap (25mg)
- (and 2 more...)
|
42 |
Male |
20 Years to 50 Years (Adult) |
NCT03208218 |
BIBE2016-02 |
|
August 17, 2016 |
August 25, 2016 |
October 31, 2016 |
July 5, 2017 |
July 6, 2017 |
|
|
|
| 15 |
NCT01198054 |
Terminated |
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) |
|
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effectivity: Duration of response with lenalidomide after conventional induction chemotherapy
- Safety and tolerability: Type and intensity of adverse events related with lenalidomide
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT01198054 |
LENA-LMA-5 |
|
January 2011 |
February 2013 |
February 2013 |
September 9, 2010 |
April 7, 2014 |
|
- Hospital General de Alicante.
Alicante, Spain - Hospital Germans Trias I Pujol
Badalona, Spain - Hospital Clínico y Provincial de Barcelona
Barcelona, Spain - (and 9 more...)
|
|
| 16 |
NCT01380106 |
Unknown † |
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma |
|
- Drug: Lenalidomide 15mg
- Drug: Lenalidomide 25mg
|
Interventional
|
Phase 2 |
- Boston VA Research Institute, Inc.
- Celgene Corporation
- Kansas City Veteran Affairs Medical Center
- (and 4 more...)
|
Other / Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.
- Duration of M-Protein response during combination therapy with Lenalidomide plus dexamethasone
- Confirmed M-Protein response
- Expression of angiogenic factors, cytokines, adhesion molecules, and myeloma biomarker expression
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT01380106 |
RV-MM-PI-0345 |
|
August 2010 |
September 2016 |
December 2016 |
June 27, 2011 |
February 2, 2016 |
|
- Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States - West Los Angeles VA Medical Center
Los Angeles, California, United States - Edward Hines Jr VA Hospital
Hines, Illinois, United States - (and 4 more...)
|
|
| 17 |
NCT02155634 |
Withdrawn |
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma |
- Multiple Myeloma
- Neoplasms
- Plasma Cells
- (and 4 more...)
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Response Rate
- Time to progression (TTP)
- (and 2 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02155634 |
CC-5013-MM-027 |
|
July 2014 |
April 2017 |
March 2021 |
June 4, 2014 |
April 10, 2018 |
|
|
|
| 18 |
NCT00847639 |
Completed |
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma |
|
|
Interventional
|
Phase 2 |
- Center for International Blood and Marrow Transplant Research
- National Marrow Donor Program
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.
- To estimate the incidences of ≥ grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide.
- To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT.
- To determine time to disease progression and overall survival after lenalidomide.
|
30 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00847639 |
07-REV |
07-REV |
February 2009 |
January 2013 |
March 2014 |
February 19, 2009 |
April 4, 2014 |
|
- City of Hope National Medical Center
Duarte, California, United States - H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States - University of Minnesota Medical Center
Minneapolis, Minnesota, United States - (and 5 more...)
|
|
| 19 |
NCT01611259 |
Completed
Has Results |
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue |
- Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
|
- Drug: Rituximab and Lenalidomide
|
Interventional
|
Phase 2 |
- Arbeitsgemeinschaft medikamentoese Tumortherapie
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease
- Number and Severity of Adverse Events
- Influence of Rituximab Plus Lenalidomide on T-cell Subsets
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT01611259 |
AGMT_MALT2 |
|
May 2012 |
May 2014 |
February 2015 |
June 4, 2012 |
November 6, 2017 |
November 6, 2017 |
- AKH Linz
Linz, Oberösterreich, Austria - Klin.Abt.f. Hämatologie; Med.Univ.Graz
Graz, Austria - Univ.-Klinik f. Innere Medizin V
Innsbruck, Austria - (and 2 more...)
|
|
| 20 |
NCT01264315 |
Active, not recruiting |
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant |
|
|
Interventional
|
Phase 2 |
- Fondazione Neoplasie Sangue Onlus
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lenalidomide toxicity and tolerability after allografting
- Lenalidomide efficacy
- Overall survival
- (and 4 more...)
|
53 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01264315 |
RV-MM-GITMO-413
2008-004529-41 |
|
September 2008 |
December 2012 |
December 2021 |
December 21, 2010 |
August 2, 2018 |
|
- A.O.U. San Giovanni Battista
Torino, Italy
|
|
| 21 |
NCT00910858 |
Completed
Has Results |
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes |
- Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
|
- Drug: Lenalidomide
- Drug: Recombinant human erythropoietin
|
Interventional
|
Phase 1
Phase 2 |
- Celgene Corporation
- Celgene
|
Industry |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide
- Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide
- PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
- (and 9 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT00910858 |
CC-5013-PK-002 |
|
January 2005 |
April 2006 |
May 2009 |
June 1, 2009 |
September 30, 2013 |
September 30, 2013 |
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 22 |
NCT02371590 |
Withdrawn |
Lenalidomide and Obinutuzumab for Previously Untreated CLL |
- Chronic Lymphocytic Leukemia
|
- Drug: Lenalidomide
- Drug: Obinutuzumab
|
Interventional
|
Phase 2 |
- University of California, San Diego
- Celgene Corporation
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The incidence of dose limiting toxicity
- Complete Response Rate
- Number of patients with adverse events associated with lenalidomide-obinutuzumab
- (and 2 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02371590 |
150342/161104 |
|
February 2018 |
December 2019 |
December 2022 |
February 25, 2015 |
February 23, 2018 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States
|
|
| 23 |
NCT01352338 |
Completed |
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) |
|
- Drug: Lenalidomide, endoxan, prednisone
- Drug: lenalidomide, endoxan, prednisone
|
Interventional
|
Phase 1
Phase 2 |
- UMC Utrecht
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT)
- phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
- phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
|
82 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01352338 |
RV-MM-PI-0630 |
REPEAT |
August 2011 |
November 2014 |
February 2016 |
May 11, 2011 |
February 26, 2016 |
|
- Antonius Ziekenhuis Nieuwegein
Nieuwegein, Utrecht, Netherlands - VU Medical Center
Amsterdam, Netherlands - UMC Utrecht
Utrecht, Netherlands
|
|
| 24 |
NCT01057121 |
Completed
Has Results |
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma |
- AIDS-Related Kaposi Sarcoma
- Recurrent Kaposi Sarcoma
|
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at Least 2/3 or 2/6 Subjects Encountering DLT (Phase I)
- Tumor Response Rate
- Time to Death
- (and 2 more...)
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT01057121 |
NCI-2012-02923
CDR0000664131
AMC-070
U01CA121947 |
|
August 2010 |
June 2014 |
June 2014 |
January 27, 2010 |
July 21, 2016 |
July 21, 2016 |
- UCLA Center for Clinical AIDS Research and Education
Los Angeles, California, United States - University of California San Diego
San Diego, California, United States - San Francisco General Hospital
San Francisco, California, United States - (and 10 more...)
|
|
| 25 |
NCT01169298 |
Completed |
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma |
- Adult T-cell Leukemia-Lymphoma
- Peripheral T-cell Lymphoma
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety of lenalidomide evaluated based on the severity of adverse events and their causality
- Response
- PK-Time to Maximum Plasma Concentration (Tmax)
- (and 7 more...)
|
13 |
All |
20 Years and older (Adult, Older Adult) |
NCT01169298 |
CC-5013-ATLL-001 |
|
July 2010 |
December 2013 |
December 2013 |
July 26, 2010 |
October 31, 2016 |
|
- National Kyusyu Cancer Center
Fukuoka, Japan - Imamura Bun-in Hospital
Kagoshima, Japan - Kumamoto University Hospital
Kumamoto, Japan - (and 3 more...)
|
|
| 26 |
NCT01270932 |
Completed |
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients |
- Renal Failure
- Multiple Myeloma
|
- Drug: Lenalidomide and Dexamethasone
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Pharmacokinetic (PK) analysis of Study drug Lenalidomide
- Evaluable for toxicity
- Evaluable for response
- Overall and progression free survival rates which will be calculated by the method of Kaplan and Meier.
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT01270932 |
RV-MM-PI-0505 |
|
November 2010 |
December 18, 2017 |
December 18, 2017 |
January 5, 2011 |
December 29, 2017 |
|
- University Health Network- Princess Margaret Hosptial
Toronto, Ontario, Canada
|
|
| 27 |
NCT01460940 |
Completed
Has Results |
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma |
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- Adult Lymphocyte Predominant Hodgkin Lymphoma
- Adult Mixed Cellularity Hodgkin Lymphoma
- (and 3 more...)
|
- Drug: panobinostat
- Drug: lenalidomide
|
Interventional
|
Phase 2 |
- Ohio State University Comprehensive Cancer Center
- Celgene
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR)
- Assess the Safety and Tolerability of Combined Lenalidomide and Panobinostat in Patients With Previously Treated Hodgkin's Lymphoma.
- Progression-free Survival in Patients With Previously Treated Hodgkin's Lymphoma Receiving Combined Lenalidomide and Panobinostat
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT01460940 |
OSU-10049
NCI-2011-03323 |
|
October 13, 2011 |
November 16, 2016 |
November 16, 2016 |
October 27, 2011 |
November 14, 2017 |
March 14, 2017 |
- Washington University
Saint Louis, Missouri, United States - The Ohio State University Medical Center
Columbus, Ohio, United States
|
|
| 28 |
NCT01718379 |
Completed |
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. |
- Myelodysplastic Syndromes
|
- Drug: Lenalidomide
- Drug: Epoetin beta
|
Interventional
|
Phase 2 |
- Groupe Francophone des Myelodysplasies
- Celgene
- Roche Pharma AG
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparing the efficacy of Lenalidomide alone to Lenalidomide with Epoetin beta in transfusion-dependent ESA-resistant
- will be to assess the safety of Lenalidomide and of its combination with Epoetin beta
|
132 |
All |
18 Years and older (Adult, Older Adult) |
NCT01718379 |
GFM-Len-Epo-08 |
|
July 2010 |
November 2012 |
June 2016 |
October 31, 2012 |
November 8, 2016 |
|
- Hematology Dpt, Service d'Hématologie Clinique
CHU Albert Michallon, Grenoble, France - Hematology Dpt, CHU de Bicêtre
Le Kremlin-Bicêtre, Ile de France, France - Hematology Dpt, CHU Cochin
Paris, Ile de France, France - (and 45 more...)
|
|
| 29 |
NCT01861340 |
Completed |
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma |
|
- Drug: Lenalidomide, Dexamethasone, and MEDI-551
|
Interventional
|
Early Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- MedImmune LLC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- The effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs).
- The safety of Medi-551 when combined with Lenalidomide and dexamethasone.
|
20 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT01861340 |
J1340
NA_00081182 |
|
May 2014 |
April 2016 |
July 2016 |
May 23, 2013 |
September 10, 2018 |
|
- The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
|
|
| 30 |
NCT01766583 |
Completed |
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma |
- Relapsed/Refractory B-cell Lymphoma
|
- Drug: CC-292 + lenalidomide
|
Interventional
|
Phase 1 |
- The Lymphoma Academic Research Organisation
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma
- preliminary efficacy signals of the CC-292 + Lenalidomide combination
- Observed maximum plasma concentration
- (and 6 more...)
|
18 |
All |
18 Years and older (Adult, Older Adult) |
NCT01766583 |
CLEAR |
CLEAR |
February 2013 |
November 2014 |
January 2018 |
January 11, 2013 |
March 7, 2018 |
|
- Hopital henri mondor
Créteil, France - CHU de Lille
Lille, France - Institut Paoli Calmette
Marseille, France - (and 3 more...)
|
|
| 31 |
NCT02898259 |
Recruiting |
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma |
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Rituximab
|
Interventional
|
Phase 1
Phase 2 |
- Case Comprehensive Cancer Center
- The Cleveland Clinic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dose of oral ixazomib
- Overall response rate
- Duration of response
- (and 4 more...)
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT02898259 |
CASE1414 |
|
February 20, 2017 |
June 2019 |
June 2024 |
September 13, 2016 |
May 18, 2018 |
|
- University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States - Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 32 |
NCT01723839 |
Active, not recruiting |
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide |
- Chronic Lymphocytic Leukemia (CLL)
|
- Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
|
Interventional
|
Phase 2 |
- Hackensack Meridian Health
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Overall Response Rate
|
54 |
All |
18 Years and older (Adult, Older Adult) |
NCT01723839 |
Pro00002262 RV-CLL-PI-0530 |
FCR |
February 22, 2012 |
January 12, 2015 |
August 2018 |
November 8, 2012 |
August 10, 2017 |
|
- John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, United States
|
|
| 33 |
NCT01582776 |
Active, not recruiting |
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma |
- Follicular Lymphoma Patients (Phase IB)
- Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
|
- Drug: Lenalidomide and GA101
|
Interventional
|
Phase 1
Phase 2 |
- The Lymphoma Academic Research Organisation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I part: Determination of the recommended dose of lenalidomide in combination with fixed doses of GA101
- Phase II part: Overall Response Rate (CR+CRu+PR) after 6 cycles
- Overall survival (OS)
- (and 6 more...)
|
317 |
All |
18 Years and older (Adult, Older Adult) |
NCT01582776 |
GALEN |
|
October 3, 2012 |
July 11, 2018 |
March 2022 |
April 23, 2012 |
August 22, 2018 |
|
- ZNA Stuivenberg
Antwerpen, Belgium - A.Z. Sint Jan AV
Bruges, Belgium - institut Jules Bordet
Bruxelles, Belgium - (and 22 more...)
|
|
| 34 |
NCT01750983 |
Active, not recruiting |
Ipilimumab and Lenalidomide in Advanced Cancer |
|
- Drug: Ipilimumab
- Drug: Lenalidomide
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Ipilimumab in Combination With Lenalidomide
- Dose-Limiting Toxicities (DLT) of Ipilimumab in Combination With Lenalidomide
- Tumor Response
|
101 |
All |
18 Years and older (Adult, Older Adult) |
NCT01750983 |
2012-0795
NCI-2013-00607 |
|
March 2013 |
March 2019 |
March 2019 |
December 17, 2012 |
July 12, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 35 |
NCT01342172 |
Terminated
Has Results |
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma |
- Urinary Bladder Neoplasms
|
|
Interventional
|
Phase 1
Phase 2 |
- Icahn School of Medicine at Mount Sinai
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: To Determine the Recommended Phase II Dose of the Combination of Gemcitabine, Cisplatin, Plus Lenalidomide
- Phase II: Progression-free Survival at 1 Year
- To Determine the Objective Response Rate to Treatment With Gemcitabine, Cisplatin, Plus Lenalidomide
- (and 4 more...)
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT01342172 |
GCO 10-1339 |
|
March 2011 |
June 2013 |
June 2013 |
April 27, 2011 |
December 15, 2014 |
November 26, 2014 |
- National Cancer Institute
Bethesda, Maryland, United States - Icahn School of Medicine at Mount Sinai
New York, New York, United States - Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
|
|
| 36 |
NCT02692339 |
Recruiting |
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Adverse events of special interest during Len/Dex therapy
- Incidence (number) of thromboembolism
- Duration of Len/Dex treatment over the course of the study
- (and 2 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT02692339 |
CC-5013-MM-028 |
PrObe-L |
February 25, 2016 |
September 29, 2023 |
September 29, 2023 |
February 26, 2016 |
March 6, 2018 |
|
- Hospital Garcia Orta, E.P.E.
Almada, Portugal - Hospital Professor Doutor Fernando Fonseca, E.P.E.
Amadora, Portugal - Hospital Central de Faro
Faro, Portugal - (and 9 more...)
|
|
| 37 |
NCT01947309 |
Terminated |
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) |
|
- Drug: Revlimid (lenalidomide)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression Free Survival (PFS)
- Response Rates
- Overall Survival (OS)
- (and 3 more...)
|
176 |
All |
18 Years and older (Adult, Older Adult) |
NCT01947309 |
NIPMS-RV-CN-001 |
|
November 2013 |
July 2016 |
September 2016 |
September 20, 2013 |
January 12, 2017 |
|
- Peking Chao-Yang Hospital
Beijing, China - Peking University People's Hospital
Beijing, China - People's Liberation Army Hospital 307
Beijing, China - (and 14 more...)
|
|
| 38 |
NCT03376477 |
Recruiting |
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients |
|
- Biological: GM-CSF vaccine
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Celgene
- Aduro Biotech, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 2-year progression free survival
- CR Conversion Rate
- MRD Conversion Rate
- (and 2 more...)
|
56 |
All |
18 Years and older (Adult, Older Adult) |
NCT03376477 |
J16118
IRB00112179 |
|
July 10, 2018 |
October 16, 2020 |
October 16, 2023 |
December 18, 2017 |
September 6, 2018 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
|
| 39 |
NCT00751296 |
Terminated
Has Results |
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) |
- Chronic Lymphocytic Leukaemia
|
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Assess the Efficacy (Response Rate) of Oral Lenalidomide in the Treatment of Patients With Symptomatic, Previously Untreated, Chronic Lymphocytic Leukemia (CLL)
- Percentage of Participants With Progression-free Survival (PFS) and Overall Survival (OS).
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT00751296 |
Rev-06-0099
RV-CLL-PI-0099 |
Rev-CLL |
August 2006 |
April 2014 |
April 2014 |
September 11, 2008 |
June 16, 2016 |
May 12, 2016 |
- University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
|
|
| 40 |
NCT01379274 |
Terminated |
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes |
|
- Drug: Lenalidomide and azacitidine combination
|
Interventional
|
Phase 2 |
- Rush University Medical Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety and tolerability of revlimid and azacitidine combination
|
2 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT01379274 |
MDS 2008-01 |
|
January 2011 |
November 2013 |
November 2013 |
June 23, 2011 |
November 28, 2013 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
|
| 41 |
NCT03110822 |
Recruiting |
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients |
|
- Drug: Ruxolitinib Oral Tablet [Jakafi]
- Drug: Lenalidomide 5Mg Oral Capsule
- Drug: Methyl Prednisolonate
|
Interventional
|
Phase 1 |
- Oncotherapeutics
- Incyte Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of maximum tolerated dose (MTD) of ruxolitinib in combination with steroids and lenalidomide [Tolerability].
- Efficacy will be measured by assessing overall response rate (ORR) and clinical benefit rate (CBR)
- Incidence of Treatment-Emergent Adverse Events [Safety]
- (and 4 more...)
|
49 |
All |
18 Years and older (Adult, Older Adult) |
NCT03110822 |
I-RUX-15-04 |
|
February 1, 2017 |
February 2020 |
May 2020 |
April 12, 2017 |
June 6, 2018 |
|
- Comprehensive Blood and Cancer Center
Bakersfield, California, United States - California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, United States - Robert A. Moss, M.D., F.A.C.P., Inc.
Fountain Valley, California, United States - (and 3 more...)
|
|
| 42 |
NCT02225275 |
Recruiting |
Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
- Drug: Lenalidomide
- Drug: Obinutuzumab
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Genentech, Inc.
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response of Combination of Lenalidomide and Obinutuzumab
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02225275 |
2014-0115
NCI-2015-00237 |
|
March 31, 2016 |
March 1, 2023 |
March 1, 2024 |
August 26, 2014 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 43 |
NCT00439231 |
Completed
Has Results |
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma
|
|
Interventional
|
Phase 2 |
- Georg Aue, M.D.
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen
|
33 |
All |
21 Years and older (Adult, Older Adult) |
NCT00439231 |
070104
07-H-0104 |
|
February 2007 |
September 2010 |
November 2010 |
February 23, 2007 |
January 13, 2014 |
January 13, 2014 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 44 |
NCT01180569 |
Withdrawn |
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma |
- Lymphoma
- Follicular Lymphoma
|
|
Interventional
|
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate (CR + PR).
- Response rate (CR + PR) and time to disease progression
- Immune monitoring and analysis of signal transduction in the lymph node.
- Immune monitoring and analysis of signal transduction in the blood.
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01180569 |
10-022 |
|
August 2010 |
May 2011 |
May 2011 |
August 12, 2010 |
September 25, 2015 |
|
|
|
| 45 |
NCT01593410 |
Completed |
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Adverse Events
- Progression Free Survival (PFS)
- (and 8 more...)
|
194 |
All |
18 Years and older (Adult, Older Adult) |
NCT01593410 |
CC-5013-MM-021 |
|
August 1, 2010 |
January 3, 2013 |
January 3, 2013 |
May 8, 2012 |
September 20, 2017 |
|
- 307 Hospital of Chinese PLA
Beijing, China - Peking University Third Hospital
Beijing, China - Peking Union Medical College Hospital
Beijing, China - (and 10 more...)
|
|
| 46 |
NCT01698801 |
Completed
Has Results |
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: dexamethasone
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Time to Response
- Duration of Response
- (and 3 more...)
|
26 |
All |
20 Years and older (Adult, Older Adult) |
NCT01698801 |
CC-5013-MM-025 |
|
October 1, 2012 |
November 26, 2013 |
June 26, 2018 |
October 3, 2012 |
November 8, 2018 |
December 3, 2014 |
- Nagoya Daini Red Cross Hospital
Nagoya, Aichi, Japan - Nagoya City University Hospital
Nagoya, Aichi, Japan - Kameda Medical Center
Kamogawa, Chiba, Japan - (and 21 more...)
|
|
| 47 |
NCT02312102 |
Active, not recruiting |
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation |
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
|
- Drug: Lenalidomide
- Drug: Velcade
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Celgene Corporation
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of Bortezomib and Lenalidomide,
- Assess clinical efficacy in terms of the number of patients experiencing a decrease in blast percentage.
- Document the remission frequency in patients receiving up to 2 induction cycles of high-dose lenalidomide combined with Velcade.
- (and 3 more...)
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT02312102 |
14-213 |
|
February 2015 |
April 2017 |
August 2019 |
December 9, 2014 |
May 11, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
| 48 |
NCT02871219 |
Recruiting |
Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma |
|
- Drug: Obinutuzumab
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) Rate
- Complete Response (CR) Rate
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT02871219 |
2015-0464
NCI-2016-01506 |
|
December 6, 2016 |
December 2019 |
December 2020 |
August 18, 2016 |
August 6, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 49 |
NCT01615042 |
Terminated |
Phase I Study of Lenalidomide in Patients With Acute Leukemia |
|
|
Interventional
|
Phase 1 |
- University of California, Davis
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (measured by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0)
- Rates of complete response (CR) and complete response without platelet recovery (CRi)
- Pharmacokinetics of high-dose lenalidomide cell activity.
- Define the effects of lenalidomide on T and Natural Killer (NK) cell activity.
|
6 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01615042 |
UCDCC#228
318008
RV_AML_PI_0696 |
|
August 2012 |
May 2017 |
May 2017 |
June 8, 2012 |
January 9, 2018 |
|
- University of California Comprehensive Cancer Center
Sacramento, California, United States
|
|
| 50 |
NCT02354313 |
Active, not recruiting |
Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients |
|
|
Interventional
|
Phase 3 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Disease-free survival (DFS)
- (and 5 more...)
|
300 |
All |
18 Years to 60 Years (Adult) |
NCT02354313 |
IIL-MCL0208
2009-012807-25 |
MCL0208 |
May 2010 |
December 2017 |
January 2019 |
February 3, 2015 |
February 9, 2018 |
|
- UO Ematologia Ospedale Dell'Angelo
Mestre, VE, Italy - SC Ematologia A.O.SS. Biagio e Antonio e C. Arrigo
Alessandria, Italy - AORN San G.Moscati
Avellino, Italy - (and 50 more...)
|
|
| 51 |
NCT01274533 |
Completed
Has Results |
Lenalidomide in HTLV-1 Adult T-Cell Leukemia |
- Adult T Cell Leukemia/Lymphoma
|
|
Interventional
|
Phase 2 |
- Columbia University
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (CR + Cru + PR)
- Safety of Lenalidomide Monotherapy
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT01274533 |
AAAE5097 |
|
December 2010 |
January 2013 |
May 2013 |
January 11, 2011 |
May 23, 2016 |
April 22, 2016 |
- Columbia University Medical Center
New York, New York, United States
|
|
| 52 |
NCT01816620 |
Completed |
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome |
|
- Drug: Lenalidomide, Dexamethasone
|
Interventional
|
Phase 2 |
- Peking Union Medical College Hospital
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hematological response rate
- Neurological response rate defined by ONLS score
- response rate of critical organs
- (and 6 more...)
|
41 |
All |
18 Years and older (Adult, Older Adult) |
NCT01816620 |
POEMS-01 |
|
March 2014 |
October 2015 |
April 2017 |
March 22, 2013 |
April 25, 2017 |
|
- Peking Union Medical College Hospital
Beijing, Beijing, China
|
|
| 53 |
NCT01703364 |
Completed |
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL |
- CLL
- Chronic Lymphocytic Leukemia
|
|
Interventional
|
Phase 1
Phase 2 |
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability of escalated starting dose
- Establishment of maximal tolerated dose (MTD) of Lenalidomide in combination with FR
- Time to MTD
- (and 4 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT01703364 |
AGMT_CLL-9
2011-004912-43 |
|
June 2012 |
March 2015 |
October 2015 |
October 10, 2012 |
May 26, 2016 |
|
- Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie
Innsbruck, Tirol, Austria - Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III
Salzburg, Austria
|
|
| 54 |
NCT01996865 |
Recruiting |
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. |
|
- Drug: Lenalidomide
- Drug: Rituximab
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL)
- Adverse Events
- Complete response rate
- (and 6 more...)
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT01996865 |
CC-5013-NHL-008 |
MAGNIFY |
April 2, 2014 |
April 8, 2023 |
July 8, 2024 |
November 27, 2013 |
October 16, 2018 |
|
- Arizona Oncology
Tucson, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Sutter East Bay Hospitals
Berkeley, California, United States - (and 111 more...)
|
|
| 55 |
NCT02322320 |
Active, not recruiting |
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) |
|
|
Interventional
|
Phase 3 |
- National Heart, Lung, and Blood Institute (NHLBI)
- Blood and Marrow Transplant Clinical Trials Network
- National Cancer Institute (NCI)
- National Marrow Donor Program
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare the PFS as a time to event analysis from randomization on the BMT CTN 0702 protocol between the three randomized treatment arms as a pairwise comparison.
- Overall survival from randomization on the BMT CTN 0702 protocol
- Event-free survival from randomization on the BMT CTN 0702 protocol
- (and 2 more...)
|
273 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02322320 |
BMTCTN07LT
U01HL069294-05 |
|
March 2015 |
December 2018 |
December 2018 |
December 23, 2014 |
September 26, 2018 |
|
- Arizona Cancer Center
Tucson, Arizona, United States - City of Hope National Medical Center
Duarte, California, United States - University of California, San Diego Medical Center
La Jolla, California, United States - (and 39 more...)
|
|
| 56 |
NCT02255162 |
Terminated |
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML |
- Acute Myeloid Leukemia (AML)
- Acute Myelocytic Leukemia
- Acute Myelogenous Leukemia
- (and 2 more...)
|
- Drug: Lenalidomide
- Genetic: HLA-mismatched stem-cell Microtransplantation
- Drug: Cytarabine
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of lenalidomide after microtransplantation
- Disease Free Survival
- Overall Survival
- (and 3 more...)
|
8 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02255162 |
14-265 |
|
January 2015 |
December 2016 |
December 2016 |
October 2, 2014 |
August 18, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 57 |
NCT02875067 |
Active, not recruiting |
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma |
- Relapsed Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
|
- Biological: Pembrolizumab
- Drug: Lenalidomide
|
Interventional
|
Phase 1
Phase 2 |
- New York University School of Medicine
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assess safety and tolerability of the combination of pembrolizumab and lenalidomide (number of drug related adverse events)
- Estimate overall response rate (ORR)
- Estimate complete response rate (CR)
- (and 7 more...)
|
7 |
All |
18 Years and older (Adult, Older Adult) |
NCT02875067 |
15-00285 |
|
August 2016 |
August 2022 |
August 2023 |
August 23, 2016 |
June 7, 2018 |
|
- Emory University Hospital
Atlanta, Georgia, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - NYU Perlmutter Cancer Center
New York, New York, United States
|
|
| 58 |
NCT02523040 |
Active, not recruiting |
A Study of Lenalidomide for Adult Histiocyte Disorders |
- Langerhans Cell Histiocytosis (LCH)
- Histiocytoses Erdheim-chester Disease
- Histiocytic Sarcoma (HS)
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression Free Survival (PFS)
- Overall Survival
- (and 4 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT02523040 |
15-197 |
|
August 2015 |
August 2019 |
August 2022 |
August 14, 2015 |
October 30, 2018 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 59 |
NCT01752075 |
Completed |
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan |
|
|
Observational
|
|
- Celgene Corporation
- Celgene
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT01752075 |
T-CC-5013-MM-009 |
|
January 2011 |
July 2013 |
July 2013 |
December 19, 2012 |
February 13, 2015 |
|
|
|
| 60 |
NCT01956695 |
Active, not recruiting |
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma |
|
- Drug: Lenalidomide
- Drug: Rituximab
|
Interventional
|
Phase 2 |
- Institut Curie
- Centre Hospitalier Universitaire, Amiens
- Institut Bergonié
- (and 8 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assess the efficacy of lenalidomide in combination with rituximab in relapsed/refractory PCNSL as measured by the objective response rate (CR + uCR + PR) at the end of the 8 cycles of induction therapy.
- The safety of the association during induction and maintenance therapy in a population of PCNSL (NCI V4)
- The duration of response
- (and 3 more...)
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT01956695 |
IC 2012-05
2012-003786-17 |
REVRI |
September 18, 2013 |
January 11, 2018 |
January 2019 |
October 8, 2013 |
April 6, 2018 |
|
- CHU Estaing
Clermont-Ferrand, Auvergne, France - CHU Bretonneau - Centre Henry Kaplan
Tours, Centre, France - Institut Bergonié
Bordeaux, Gironde, France - (and 9 more...)
|
|
| 61 |
NCT00699842 |
Terminated
Has Results |
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients |
- Myelodysplastic Syndrome
- MDS
- Low to Intermediate-1 MDS
- Non-deletion 5q
|
|
Interventional
|
Phase 1
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Celgene Corporation
- Thomas Jefferson University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine CR, PR, and Rate of Stable Disease in MDS Patients
- Safety With Dose Escalation
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT00699842 |
07C.446
RV-MDS-PI-244
2007-31 |
|
July 2008 |
January 2011 |
May 2012 |
June 18, 2008 |
November 29, 2016 |
June 3, 2014 |
- Associates in Hematology-Oncology, PC
Chester, Pennsylvania, United States - Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 62 |
NCT01919619 |
Recruiting |
Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT) |
- Blood And Marrow Transplantation
- Leukemia
- Lymphoma
|
- Drug: Lenalidomide
- Drug: Ipilimumab
|
Interventional
|
Early Phase 1 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01919619 |
2012-0947
NCI-2013-02213 |
|
November 2013 |
November 2019 |
November 2019 |
August 9, 2013 |
July 18, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 63 |
NCT03232307 |
Not yet recruiting |
Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) |
- Hematopoietic/Lymphoid Cancer
- Mantle Cell Lymphoma
|
- Drug: Ibrutinib
- Drug: Rituximab
- Drug: Lenalidomide
- Drug: Dexamethasone Sodium Sulfate
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene
- Janssen Scientific Affairs, LLC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) at 4 Months of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
- Summary of Adverse Events of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
|
40 |
All |
66 Years and older (Older Adult) |
NCT03232307 |
2016-0280
NCI-2018-01271 |
|
November 2018 |
November 2023 |
November 2023 |
July 27, 2017 |
October 9, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 64 |
NCT00812968 |
Completed
Has Results |
Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality. |
- Myelodysplastic Syndromes
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AE)
- Maximum Observed Plasma Concentration (Cmax) of Lenalidomide
- Time to Maximum Plasma Concentration (Tmax) of Lenalidomide
- (and 17 more...)
|
11 |
All |
20 Years and older (Adult, Older Adult) |
NCT00812968 |
CC-5013-MDS-007 |
|
September 2007 |
September 2010 |
September 2010 |
December 22, 2008 |
December 12, 2016 |
December 17, 2013 |
- Celgene Clinical Site
Shimono, Tochigi, Japan - Celgene Clinical Site
Shibuya-ku, Tokyo, Japan - Celgene Clinical Site
Hiroshima, Japan - (and 3 more...)
|
|
| 65 |
NCT01111903 |
Completed |
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse |
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of lenalidomide as single agent, then DMT of lenalidomise with carboplatin and pegylated liposomal doxorubicin
- Safety profile of lenalidomide as single agent, then in combination
|
67 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01111903 |
REV (GINECO-OV214) |
REV |
May 2009 |
December 2014 |
December 2014 |
April 28, 2010 |
March 17, 2016 |
|
- Hopital Tenon
Paris, France
|
|
| 66 |
NCT02589145 |
Active, not recruiting |
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype |
|
- Drug: Lenalidomide
- Drug: Vorinostat
- Drug: Gemcitabine
- (and 10 more...)
|
Interventional
|
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Lenalidomide with Vorinostat, Gemcitabine, Busulfan, Melphalan and Autologous Stem-Cell Transplant z(ASCT)
- Event Free Survival of Lenalidomide with Vorinostat, Gemcitabine, Busulfan, Melphalan and Autologous Stem-Cell Transplant (ASCT)
|
8 |
All |
15 Years to 65 Years (Child, Adult, Older Adult) |
NCT02589145 |
2015-0558
NCI-2015-01938 |
|
June 22, 2016 |
June 2021 |
June 2021 |
October 28, 2015 |
May 23, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 67 |
NCT00783367 |
Active, not recruiting |
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
- Follicular Lymphoma
- Marginal Zone B-Cell Lymphoma
- MALT Lymphoma
- (and 4 more...)
|
- Drug: lenalidomide-low dose dexamethasone plus rituximab
- Drug: Lenalidomide + Rituximab
|
Interventional
|
Phase 2 |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate to lenalidomide-dexamethasone + rituximab therapy in relapsed small B-cell lymphoma with rituximab resistance
- Time until progression after lenalidomide-dexamethasone + rituximab therapy in relapsed small B-cell lymphomas with rituximab resistance
- Compare the response rate for the previous rituximab-containing regimen to that obtained subsequently to lenalidomide-dexamethasone + rituximab therapy
- Determine the toxicity profile of lenalidomide-dexamethasone + rituximab therapy in patients who have received a previous rituximab-containing combination regimen
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT00783367 |
UPCC 02408
UPenn IRB#807684
RV-NHL-PI-0296 |
|
July 2008 |
December 2013 |
|
October 31, 2008 |
January 25, 2017 |
|
- University of Pennsylvania; Abramson Cancer Center; Lymphoma Program
Philadelphia, Pennsylvania, United States
|
|
| 68 |
NCT01421927 |
Completed |
Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma |
|
|
Interventional
|
Phase 1 |
- University Hospital, Bordeaux
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of lenalidomide
- One-year Progression-Free Survival
- One-year Overall Survival
- (and 6 more...)
|
13 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01421927 |
CHUBX 2010/01 |
REVALLO |
August 2011 |
October 2014 |
October 2014 |
August 23, 2011 |
July 23, 2015 |
|
- CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, France
|
|
| 69 |
NCT01553786 |
Active, not recruiting |
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) |
|
|
Interventional
|
Phase 2 |
- The Lymphoma Academic Research Organisation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
80 |
All |
60 Years to 80 Years (Adult, Older Adult) |
NCT01553786 |
REVAIL |
|
November 2011 |
March 2018 |
March 2020 |
March 14, 2012 |
October 12, 2018 |
|
- Université Catholique de Louvain Saint Luc
Bruxelles, Belgium - Universitair Ziekenhuis Gent
Gent, Belgium - Université Catholique de Louvain Mont Godinne
Yvoir, Belgium - (and 27 more...)
|
|
| 70 |
NCT01038635 |
Completed
Has Results |
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) |
|
- Drug: 5-Azacytidine
- Drug: Lenalidomide
|
Interventional
|
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA)
- Overall Response Rate (ORR) of Lenalidomide in Combination With 5-azacytidine (5-AZA) in Participants With Leukemia
- Overall Response: Number of Participants With CR or CRi Response
|
94 |
All |
Child, Adult, Older Adult |
NCT01038635 |
2009-0467
NCI-2011-01941 |
|
December 2009 |
November 2015 |
November 2015 |
December 24, 2009 |
February 10, 2017 |
February 10, 2017 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 71 |
NCT01995669 |
Recruiting |
Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma |
|
- Drug: Lenalidomide
- Drug: Obinutuzumab (GA101)
|
Interventional
|
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene
- Genentech, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Lenalidomide plus Obinutuzumab
- Objective Response
|
72 |
All |
18 Years and older (Adult, Older Adult) |
NCT01995669 |
2013-0261
NCI-2014-00943 |
|
May 2014 |
May 2019 |
May 2019 |
November 26, 2013 |
August 6, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 72 |
NCT01032291 |
Terminated
Has Results |
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer |
|
- Drug: cetuximab
- Drug: lenalidomide
|
Interventional
|
Phase 2 |
- Celgene Corporation
- Celgene
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period
- Percentage of Participants With a Response to Treatment During the Proof of Concept Period
- Kaplan-Meier Estimates for Progression Free Survival (PFS)
- (and 4 more...)
|
51 |
All |
18 Years and older (Adult, Older Adult) |
NCT01032291 |
CC-5013-COLO-001
2009-012665-61 |
|
December 2009 |
January 2011 |
January 2011 |
December 15, 2009 |
May 21, 2013 |
May 21, 2013 |
- Flinders Medical Centre, Dept. of Oncology
Bedford Park, South Australia, Australia - UZ Antwerpen Dept. of Medical Oncology
Antwerp, Belgium - ULB Erasme Service de Gastroenterologie
Brussels, Belgium - (and 14 more...)
|
|
| 73 |
NCT01433965 |
Recruiting |
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome |
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
|
|
Interventional
|
Phase 1 |
- University of California, Davis
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0 and Graft versus Host Disease Staging
- Disease relapse
- Disease-free survival
- Incidence of Graft versus Host disease
|
24 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01433965 |
111792
UCDCC#227 |
|
August 2012 |
October 2018 |
December 2019 |
September 14, 2011 |
March 2, 2018 |
|
- University of California Davis
Sacramento, California, United States
|
|
| 74 |
NCT00799513 |
Unknown † |
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma |
- Diffuse Large B-cell Lymphoma
|
|
Interventional
|
Phase 2 |
- IRCCS San Raffaele
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1-year progression-free survival
- Median overall survival, response rate, response duration
|
47 |
All |
65 Years and older (Older Adult) |
NCT00799513 |
2008-003729-18 |
|
October 2009 |
October 2013 |
November 2013 |
December 1, 2008 |
March 22, 2012 |
|
- San Raffaele Scientific Institute
Milan, Italy
|
|
| 75 |
NCT03411031 |
Recruiting |
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide |
|
- Drug: Elotuzumab
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Response Rate (ORR)
- Minimum Response (MR)
- Time to Next Treatment (TTNT)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03411031 |
MCC-19197
NCI-2018-00891 |
|
May 7, 2018 |
April 2021 |
April 2022 |
January 25, 2018 |
October 3, 2018 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 76 |
NCT00478959 |
Completed |
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma |
|
- Drug: Lenalidomide (Revlimid®)
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the response rate (CR + CRu + PR) of Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00478959 |
CC-5013-HL |
|
December 2006 |
June 2014 |
June 2014 |
May 25, 2007 |
October 10, 2018 |
|
|
|
| 77 |
NCT00874978 |
Unknown † |
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality |
- Myelodysplastic Syndromes
|
|
Interventional
|
Phase 2 |
- King's College Hospital NHS Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Red blood cell (RBC) transfusion independence.
- Cytogenetic response
- Over or equal to 50% decrease in RBC transfusion requirements
- (and 7 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT00874978 |
04CC06
REC - 04/Q0703/148
EudraCT - 2004-005101-29 |
|
January 2005 |
December 2015 |
December 2015 |
April 3, 2009 |
September 2, 2015 |
|
- King's College Hospital NHS Foundation Trust
London, United Kingdom
|
|
| 78 |
NCT03106324 |
Recruiting |
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant |
|
- Drug: Revlimid (lenalidomide)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of cardiovascular events
- Incidence of renal impairment in NDMM patients
- Incidence of infections in NDMM patients
- Incidence of Second primary malignancy (SPM) in TNE NDMM patients treated with any first line regimen
|
888 |
All |
18 Years and older (Adult, Older Adult) |
NCT03106324 |
CC-5013-MM-034
U1111-1194-5810 |
|
March 31, 2017 |
March 31, 2025 |
March 31, 2025 |
April 10, 2017 |
October 25, 2018 |
|
- Innsbruck University Hospital
Innsbruck, Austria - LKH Hochsteiermark
Leoben, Austria - University hospital St. Pölten
Polten, Austria - (and 85 more...)
|
|
| 79 |
NCT00761449 |
Completed |
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 |
|
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Major cytogenetic response (50% or more reduction of the del5(q) or monosomy 5 FISH positive clone in the bone marrow using the LSI EGR1/D5S23,D5S721 FISH probe) after 16 weeks of lenalidomide treatment
- Minor and complete cytogenetic (FISH) response after 8 and 16 weeks
- Red blood cell transfusion independence
- (and 4 more...)
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT00761449 |
NMDSG07A
EudraCT no: 2007-000450-31 |
|
October 2007 |
December 2009 |
December 2009 |
September 29, 2008 |
April 27, 2012 |
|
- Department of Hematology, Aalborg Hospital
Aalborg, Denmark - Department of Hematology, Aarhus University Hospital
Aarhus, Denmark - Department of Hematology, Rigshospitalet
Copenhagen, Denmark - (and 15 more...)
|
|
| 80 |
NCT00655668 |
Terminated
Has Results |
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma |
- T-cell Non-Hodgkin's Lymphoma
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Participants Categorized by Best Response as Determined by Investigator
- Duration of Response
- Time-to-Progression
- (and 2 more...)
|
54 |
All |
18 Years and older (Adult, Older Adult) |
NCT00655668 |
CC-5013-TCL-001
2007-002171-13 |
EXPECT |
March 2008 |
March 2010 |
April 2010 |
April 10, 2008 |
March 1, 2017 |
January 5, 2012 |
- Tower Cancer Research Foundation
Beverly Hills, California, United States - Cancer Center of Kansas
Wichita, Kansas, United States - Hackensack University Medical Center
Hackensack, New Jersey, United States - (and 42 more...)
|
|
| 81 |
NCT03283046 |
Withdrawn |
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma |
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- Multiple Myeloma
|
- Drug: Nivolumab
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Ipilimumab
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma
- Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma
- Rate of Response of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma
- (and 4 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT03283046 |
2016-0482 |
|
October 2017 |
October 2020 |
October 2020 |
September 14, 2017 |
September 20, 2017 |
|
|
|
| 82 |
NCT00981708 |
Unknown † |
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) |
|
- Drug: Lenalidomide, Dexamethasone and Cyclophosphamide
|
Interventional
|
Phase 1
Phase 2 |
- University of Athens
- Hellenic Cooperative Oncology Group
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the maximum tolerated dose of lenalidomide and cyclophosphamide and assess the hematologic response rate of the combination of Cyclophosphamide/Dexamethasone plus lenalidomide in patients with AL amyloidosis.
- To assess the toxicity of Cyclophosphamide/Dexamethasone plus lenalidomide combination in patients with AL amyloidosis and organ response rate
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT00981708 |
RV-178 |
|
February 2008 |
December 2011 |
February 2015 |
September 22, 2009 |
January 31, 2014 |
|
- Alexandra Hospital , Department of Clinical Therapeutics
Athens, Attica, Greece
|
|
| 83 |
NCT01207921 |
Active, not recruiting |
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma |
|
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT, as measured by dropout rate.
- Overall survival (OS)
- Adverse event profile
- (and 4 more...)
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT01207921 |
201010719 |
|
April 28, 2011 |
September 19, 2016 |
October 31, 2018 |
September 23, 2010 |
June 21, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States - Wake Forest University
Winston-Salem, North Carolina, United States - Ohio State University
Columbus, Ohio, United States
|
|
| 84 |
NCT01463670 |
Active, not recruiting |
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance |
|
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Montefiore Medical Center
- State University of New York - Downstate Medical Center
- (and 5 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall response rate (ORR)
- toxicity
|
11 |
All |
18 Years and older (Adult, Older Adult) |
NCT01463670 |
11-107 |
|
October 2011 |
October 2019 |
October 2019 |
November 2, 2011 |
April 18, 2018 |
|
- Stamford Hospital
Stamford, Connecticut, United States - Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States - (and 8 more...)
|
|
| 85 |
NCT00704691 |
Terminated |
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas |
- Peripheral T-cell Lymphomas
- Adult T-cell Leukemia
- Adult T-cell Lymphoma
- (and 5 more...)
|
|
Interventional
|
Early Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate to lenalidomide (CR,PR and unconfirmed complete responses
- Toxicity of lenalidomide
|
1 |
All |
19 Years and older (Adult, Older Adult) |
NCT00704691 |
F071108004
UAB 0663 |
|
June 2008 |
July 2009 |
December 2009 |
June 25, 2008 |
April 20, 2012 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 86 |
NCT00901615 |
Completed |
Lenalidomide and R-CHOP in B-cell Lymphoma |
- Lymphoma, Large B-Cell, Diffuse
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
|
- Drug: Lenalidomide and R-CHOP
|
Interventional
|
Phase 1
Phase 2 |
- Lymphoma Study Association
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Dose Limiting Toxicities
- Complete response rate and Overall response rate at the end of treatment
- Complete and Overall response rates after induction
- (and 3 more...)
|
108 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00901615 |
R2CHOP-1 |
R2CHOP-1 |
January 6, 2009 |
November 19, 2010 |
November 23, 2015 |
May 14, 2009 |
August 23, 2018 |
|
- CHU de Dijon
Dijon, France - CHRU Lille
Lille, France - CHU Lyon Sud
Pierre Benite, France - (and 2 more...)
|
|
| 87 |
NCT01254578 |
Completed |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- (and 39 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Lenalidomide
- Other: Pharmacological Study
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of lenalidomide after allogeneic hematopoietic stem cell transplantation graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0
- Overall response in patients treated with lenalidomide according to the International Working Group (IWG) criteria
|
17 |
All |
18 Years and older (Adult, Older Adult) |
NCT01254578 |
NCI-2011-02551
OSU 10079
OSU-10079
CDR0000688918
2010C0069
OSU-2010C0069
8305
P30CA016058
U01CA076576 |
|
November 24, 2010 |
November 9, 2012 |
November 9, 2012 |
December 6, 2010 |
September 25, 2017 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
|
| 88 |
NCT00675441 |
Terminated
Has Results |
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD) |
- Graft-versus-Host Disease
|
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants' With Treatment Response of Complete or Partial Response
|
5 |
All |
18 Years and older (Adult, Older Adult) |
NCT00675441 |
2006-0321 |
|
April 2008 |
August 2011 |
August 2011 |
May 9, 2008 |
December 11, 2013 |
December 11, 2013 |
- UT MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 89 |
NCT00923663 |
Unknown † |
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type |
|
|
Interventional
|
Phase 2 |
- Medical University of Vienna
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of objective responses induced by Lenalidomide
- Time to progression
|
16 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00923663 |
LEN-MALT |
|
July 2009 |
June 2011 |
June 2011 |
June 18, 2009 |
September 28, 2010 |
|
- Dept of Internal Medicine
Vienna, Austria
|
|
| 90 |
NCT01316523 |
Active, not recruiting |
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma |
|
- Drug: Rituximab
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- University of California, Davis
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate to treatment
- Time to progression
- Overall survival
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01316523 |
215856
UCDCC#224
RV_PI_NHL_0488 |
|
December 2010 |
December 2018 |
July 2019 |
March 16, 2011 |
July 18, 2018 |
|
- University of California Davis Cancer Center
Sacramento, California, United States - Sutter Pacific Medical Foundation
Santa Rosa, California, United States
|
|
| 91 |
NCT01243476 |
Active, not recruiting |
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome |
|
- Drug: Lenalidomide
- Other: Placebo
|
Interventional
|
Phase 3 |
- Fundación General de la Universidad de Salamanca
- Celgene Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Period until the progression of myelodysplastic syndrome
- Safety
- Erythroid response
- (and 7 more...)
|
61 |
All |
18 Years and older (Adult, Older Adult) |
NCT01243476 |
SINTRA-REV
2009-013619-36 |
SINTRA-REV |
January 2010 |
September 2021 |
January 2022 |
November 18, 2010 |
April 26, 2018 |
|
- Hospital de Cabueñes
Gijón, Asturias, Spain - Hospital Central de Asturias
Oviedo, Asturias, Spain - Hospital Universitari Germans Trias i Pujol (ICO Badalona)
Badalona, Barcelona, Spain - (and 11 more...)
|
|
| 92 |
NCT01373294 |
Active, not recruiting
Has Results |
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer |
|
- Drug: Bacille Calmette-Guerrin (BCG)
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- Celgene Corporation
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Arm A: Progression Free Survival (PFS)
- Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
|
17 |
All |
18 Years and older (Adult, Older Adult) |
NCT01373294 |
MCC-16295
RV-BLD-PI-0330 |
|
November 30, 2011 |
January 9, 2015 |
December 2019 |
June 14, 2011 |
June 8, 2018 |
May 12, 2016 |
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 93 |
NCT01583283 |
Active, not recruiting |
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma |
|
- Drug: ACY-1215
- Drug: lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Establish optimal dose of ACY-1215 in combination with lenalidomide and dexamethasone
- Evaluate safety by assessing toxicities
- Determine the preliminary anti-tumor activity of ACY-1215 in combination with lenalidomide and dexamethasone
- (and 2 more...)
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT01583283 |
ACE-MM-101 |
|
July 12, 2012 |
January 30, 2019 |
January 30, 2019 |
April 24, 2012 |
October 2, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - University of North Carolina
Chapel Hill, North Carolina, United States - (and 2 more...)
|
|
| 94 |
NCT01241734 |
Unknown † |
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL |
- Diffuse Large B-cell Lymphoma.
|
|
Interventional
|
Phase 1
Phase 2 |
- Hackensack Meridian Health
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Stage 1 - Safety (type, frequency, severity and relationship of adverse events to study treatment) and tolerability
- Stage 1 - Overall response rate (CR, PR, SD)
- Stage 2 - Proportion of patients with a stem cell collection of at least 3x106 CD34+ cells prior to ASCT
- (and 4 more...)
|
67 |
All |
18 Years and older (Adult, Older Adult) |
NCT01241734 |
Pro00001132 - RV-DLBCL-PI-0463 |
RICER |
June 2010 |
December 2014 |
December 2014 |
November 16, 2010 |
February 4, 2014 |
|
- John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States - Duke University Medical Center
Durham, North Carolina, United States
|
|
| 95 |
NCT01133275 |
Active, not recruiting
Has Results |
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS |
- Myelodysplastic Syndrome
- MDS
|
- Drug: Prednisone
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Erythroid Response
- Number of Participants With Grade 3 or 4 Adverse Events Possibly Related to Treatment
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT01133275 |
MCC-16099
RV-MDS-PI-0456
25005/1 |
|
April 28, 2010 |
January 31, 2015 |
June 2019 |
May 28, 2010 |
November 7, 2018 |
January 18, 2016 |
- University of Florida Shands Cancer Center
Gainesville, Florida, United States - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 96 |
NCT02041325 |
Completed
Has Results |
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias |
|
- Drug: Lenalidomide
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Boston VA Research Institute, Inc.
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
|
- Positive for Hepatitis B Surface Antigen
- Safety
- Quantity of Subjects With a T-cell Response
- Phenotypic Changes
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT02041325 |
IRB 1831 |
|
April 2005 |
January 2011 |
April 2014 |
January 22, 2014 |
May 17, 2016 |
May 17, 2016 |
- VA Boston Healthcare System
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 97 |
NCT02038153 |
Unknown † |
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant |
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 14 more...)
|
- Drug: Lenalidomide
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 1
Phase 2 |
- Albert Einstein College of Medicine, Inc.
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse free survival rate
- Overall survival
|
48 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT02038153 |
13-08-148
NCI-2013-02493
P30CA013330 |
|
December 2013 |
January 2016 |
January 2017 |
January 16, 2014 |
March 3, 2015 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States - Montefiore Medical Center - Moses Campus
Bronx, New York, United States
|
|
| 98 |
NCT01011894 |
Completed
Has Results |
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age |
- Chronic Lymphocytic Leukemia
- Leukemia
|
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
26 |
All |
65 Years and older (Older Adult) |
NCT01011894 |
09-045 |
|
November 6, 2009 |
February 23, 2016 |
February 23, 2016 |
November 11, 2009 |
May 18, 2017 |
May 18, 2017 |
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 99 |
NCT01718743 |
Active, not recruiting |
MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients |
|
- Drug: Lenalidomide
- Drug: MLN9708
- Radiation: Questionnaires
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) with Combination of MLN 9708 with Lenalidomide
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT01718743 |
2012-0277
NCI-2012-02873 |
|
December 2012 |
December 2019 |
December 2020 |
October 31, 2012 |
March 23, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 100 |
NCT00933426 |
Terminated |
Lenalidomide and Paclitaxel in Prostate Cancer |
|
- Drug: Lenalidomide
- Drug: Paclitaxel
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of Lenalidomide in Combination with Low-Dose Weekly Paclitaxel
- Progression-Free (PFS) Time in Patients with a Lymph Node Dominant Clinical Phenotype
|
17 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00933426 |
2008-0606
NCI-2010-01039 |
|
August 2009 |
December 2015 |
December 2015 |
July 7, 2009 |
October 26, 2016 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
Create an RSS feed from your search for:
Download the search results for: